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Data from Healthy Volunteers
As the number of successful diagnoses grows, presumably
many of us are becomingmore comfortablewith large-scale
sequencing as an approach to diagnostic testing. What
happens when instead of looking for the culprit variant in
a person with a rare disease, you use the sequence as a crys-
tal ball? That is, how do you cull genome sequence data
from healthy adults in order to make clinical use of the in-
formation therein? To get a sense of what to expect when
large-scale sequencing comes to the masses, a Stanford
group performed whole-genome sequencing of 12 healthy
volunteers. Their recent publicationoutlines the challenges
they faced along theway, fromtechnical issues to the cost of
manpower. At several points in their pipeline, they took the
opportunity to assess ambiguity, including genotype
discordance between sequence platforms, discrepancies in
variant classification between individuals curating the
data, and differences in the clinical interpretation and pro-
posed follow-up by an independent group of physicians.
This work provides food for thought as the movement to-
ward personal genomes heats up. Don’t miss the sample
report at the end of the supplemental materials.
Dewey et al. (2014). JAMA 311, 1035–1045.
Back and Forth
Because it is tricky to genotype genetic inversions, our un-
derstanding of them has lagged behind that of many other
types of genetic variation, and few population studies have
been performed to characterize them in detail. Aguado
et al. optimized a high-throughput PCR-based method to
do just this. Using this inverse PCR protocol, they vali-
dated 17 putative inversions in humans and then geno-
typed them in 77 individuals and in nonhuman primates.
Some of the inversions were quite common with a minor
allele frequency as high as 49%. It is generally assumed
that such polymorphic inversions occurred once and
then spread. This seemed to be the case for some of the in-
versions analyzed, but for others, the same region seemed
to have flipped over repeatedly during evolution. Besides
being interesting from a genome-evolution standpoint,
this also means that the orientation of these regions
cannot be inferred from SNP genotypes. Thus, any disease
associations mediated by these inversions would be unde-
tectable by SNP-based association studies.
Aguado et al. (2014). PLOS Genet. 10, e1004208.1Department of Human Genetics, Emory University School of Medicine, Atlan
*Correspondence: kgarber@genetics.emory.edu
http://dx.doi.org/10.1016/j.ajhg.2014.04.007. 2014 by The American Societ
The AmCell-free DNA: Not Just for Prenatal Testing
The use of cell-free DNA for the detection of aneuploidy in
pregnantwomenhas been rapidly incorporated into prena-
tal screening, but is not the only clinical application of cell-
free-DNA testing. Tumors release short cell-free DNA frag-
ments that can be detected in the circulation, and several
groups have been exploring the use of these fragments for
detection andmonitoring of cancer. One oncology applica-
tion that was recently explored by Thierry et al. is the detec-
tion of KRAS and BRAFmutations associated with metasta-
tic colorectal cancer. KRAS mutations predict resistance to
treatment with anti-epidermal growth factor receptor
(EGFR) antibodies and are used for deciding who is a candi-
date for these drugs, whereas certain BRAF mutations are
associated with poor prognosis. In a prospective blinded
study, the researchers compared mutation results obtained
from cell-free DNA with those from direct analysis of
tumor tissue from the same patients. Compared to the
gold standard approach, the new method achieved 93%
sensitivity and 98% specificity. Even among those patients
whoare candidates for anti-EGFRtherapy,mostwill develop
resistance over time as a result of acquiredmutations. Thus,
it is plausible that the cell-free techniquemight also be use-
ful for monitoring patients who are on these therapies for
mutations that predict the development of resistance.
Thierry et al. (2014). Nat. Med. 20, 430–435.
A Thrifty Gene?
Jim Neel first proposed the so-called ‘‘thrifty-gene hypoth-
esis,’’ which states that the genetic variation that was
advantageous under historical conditions leaves us suscep-
tible to diseases such as diabetes and obesity under modern
conditions. Although it makes sense, little evidence has
been found to directly support this idea. Natural selection
based on dietary preferences does seem to have influenced
copy-number variation (CNV) encompassing AMY1 and
AMY2, the genes encoding salivary and pancreatic
amylase, respectively, which are enzymes that help us
digest starch; populations with a high-starch diet are
more likely to have a high copy number. Falchi et al.
have now found evidence that this CNV influences our
health risks with a modern diet. Through a gene-centric
association study of commonCNV, they found that having
fewer copies of the amylase CNV is associated with higher
body mass index and increased risk of obesity. The associ-
ation is attributable to AMY1, which can be found inta, GA 30322, USA
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2–14 copies per individual and whose encoded protein
amount in serum is correlated with the number of gene
copies. Although important for initiating carbohydrate
digestion in the mouth, AMY1 also seems to be highly ex-
pressed in adipose tissue, so either or both locations might
be important for the association. Prior to this study, one of
the most well-documented genetic associations with
obesity was with FTO; the link with AMY1 copy number
appears to be stronger, and because it is multiallelic, there
is a range of obesity risk that spans up to an 8-fold differ-
ence between those individuals with the highest copy
number and those with the lowest.
Falchi et al. (2014). Nat. Genet. Published online March 30,
2014. http://dx.doi.org/10.1038/ng.2939.
If You Screen, Will They Test?
A significant fraction of individuals with the hereditary
colorectal cancer Lynch syndrome go undetected, and
this fact serves as the rationale for universal screening of
colorectal tumors for indications of Lynch syndrome.
Although the technical approaches to this screening differ
and can include microsatellite-instability testing and/or
immunohistochemistry for mismatch repair proteins, the648 The American Journal of Human Genetics 94, 647–648, May 1, 2goal is to identify patients for further follow-up and
genetic testing. If few people follow through with testing,
it negates the screening effort. To explore follow-up rates
and the factors that might influence it, Cragun et al.
surveyed key stakeholders from 15 institutions that have
undertaken universal screening of colorectal tumors for
at least 6 months. Of those patients with abnormal tumor
screening, the estimated follow-through rates for genetic
testing at these institutions ranged from less than 10%
to more than 85%. Apparently, just screening isn’t
enough; a whole system must be put in place to manage
the downstream process so that at-risk patients receive
the counseling and testing intended by the screening
program. Information from this survey highlights imple-
mentation strategies that might lead to greater success in
patient follow-through. In programs with higher follow-
through rates, patients with positive results were given
this information by genetic counselors or genetic nurse
counselors. These programs also tended to have pro-
cesses that reduced barriers to patient access to genetic
professionals.
Cragun et al. (2014). Genet. Med. Published online March
20, 2014. http://dx.doi.org/10.1038/gim.2014.31.This Month in Our Sister JournalsGOing from Association to Function
One way that researchers have attempted to understand
the results of genome-wide association studies (GWASs) is
to apply a gene ontology (GO) analysis based on the
SNPs associated with the trait of interest. If the SNPs impli-
cated in the GWAS can be linked to a biological pathway,
the pathway provides a functional target for understand-
ing how the trait arises. Typically, researchers create a list
of genes containing the SNPs that were implicated in theGWAS and then look for more than the expected number
of genes in this list to be linked to a certain GO term. In
their recent paper, Szkiba et al. showed that the assump-
tions made in these strategies are not always valid. They
proposed an alternative method called SNP2GO, which
looks for overrepresentation of candidate SNPs with a
GO term.
Szkiba et al. (2014). Genetics. Published online February 21,
2014. http://dx.doi.org/10.1534/genetics.113.160341.014
